Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell
analysis solutions company, officially announced its Enhanced Small
Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and
Cytek Northern Lights™ cell analysis systems. With this optional
upgrade, these systems show superior sensitivity and resolution of
subcellular materials, including extracellular vesicles (EVs),
while maintaining high resolution and high parameter capabilities
for cell analysis, making them the preferred choice among
researchers and clinicians.
Exosomes are the most commonly studied EV, with
a market estimated to increase from $227.5 million in 2023 to $1.3
billion by 2028, at a compound annual growth rate (CAGR) of 42.2%
from 2023 through 20281. Researchers studying exosomes, as well as
viruses, small bacteria, and nanoparticles, are moving to flow
cytometry because of its high throughput and quantitative detection
capabilities. Typically, flow cytometers have been unable to detect
particles smaller than 500 nm, limiting their use to the study of
cells and larger particles. Now, particles as small as 70 nm can be
studied label-free on Cytek’s Full Spectrum Profiling™ (FSP™)
analyzers, giving researchers the ability to characterize the full
emission spectra of small particles. Cytek is now positioned to be
a leader in the growing small particle research market.
With Cytek’s new ESP Detection Option, the
rapidly growing areas of research conducted on viruses, small
bacteria, EVs, nanoparticles, and other subcellular particles for
therapy development and biomedical research are being
advanced. EVs can be used in various applications such as
biomarker development, diagnostic tools and therapeutic development
for delivery of drugs.
“Quantitative measurements of individual EVs are
critical to progress in the field, and the excellent fluorescence
performance of the Cytek Aurora and Northern Lights systems enables
us to make sensitive measurements of both EV size and cargo,” noted
the Scintillon Research Institute’s John Nolan, Ph.D. “The new ESP
Detection Option provides greatly increased light scatter
sensitivity, enabling the discrimination of EV sub-populations with
distinctive composition and ultra structure that can affect light
scattering. These capabilities empower us to better understand the
biogenesis of different types of EVs as well as their biological
functions toward using these to both detect and treat disease.”
Added Ming Yan, Ph.D., CTO of Cytek Biosciences,
“Cytek’s Aurora and Northern Lights systems have helped
revolutionize immunology research and single cell analysis. With
the introduction of the ESP Detection Option, we are providing new
tools to advance small particle biomedical research and further our
mission to provide a complete cell analysis solution to our
customers. Bringing improved speed and accuracy to the study of
extracellular vesicles, cell to cell communication, and cell
signaling in many disease and physiological states, we expect to
accelerate the pace of discovery, therapy and diagnostic
development, and benefit the community.”
The ESP Detection Option on the Cytek Northern
Lights and Cytek Aurora systems adds to Cytek's portfolio of small
particle solutions, including the Cytek Amnis® ImageStream®X Mk II
imaging flow cytometer, which enables detection of EV production
and captures images of EV uptake by cells.
For availability details and
more information on Cytek’s new ESP Detection Option on the
Cytek Aurora and Northern Lights systems, please visit
https://cytekbio.com/pages/esp.
About Cytek Biosciences,
Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell
analysis solutions company advancing the next generation of cell
analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail
preparation system, and reagents, software and services to provide
a comprehensive and integrated suite of solutions for its
customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, ESP, Full Spectrum Profiling, FSP, Cytek
Aurora, Northern Lights, Cytek Orion, Amnis, Guava and ImageStream
are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s business, product plans and
strategies; the estimated exosomes market size, growth and CAGR
from 2023 through 2028; Cytek’s ability to be a leader in the
growing small particle research market; Cytek’s mission to provide
a complete cell analysis solution to its customers; and Cytek’s
ability to accelerate the pace of discovery, therapy and diagnostic
development and benefit the community. These statements are based
on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management.
These statements also deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to global economic and market conditions; competition;
market acceptance of Cytek’s current and potential products;
Cytek’s dependence on certain sole and single source suppliers;
Cytek’s ability to manage the growth and complexity of its
organization; Cytek’s ability to manage relationships with key
customers and suppliers; Cytek’s ability to retain key employees;
and Cytek’s ability to continue to stay in compliance with its
material contractual obligations, applicable laws and regulations.
You should refer to the section entitled “Risk Factors” set forth
in Cytek’s most recent Quarterly Report on Form 10-Q filed with the
SEC and other filings Cytek Biosciences makes with the SEC from
time to time for a discussion of important factors that may cause
actual results to differ materially from those expressed or implied
by Cytek’s forward-looking statements. Although Cytek believes that
the expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
1 Exosome Diagnostics, Therapeutics and Research Tools: Global
Markets by BCC Research, May 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Oct 2023 to Oct 2024